Want to see ABVX full AI Analyst Report?
ABVX Stock Chart & Stats
$125.70
$2.30(1.83%)
At close: 4:00 PM EDT
$125.70
$2.30(1.83%)
Day’s Range― - ―
52-Week Range$67.15 - $148.83
Previous Close$127
Volume662.35K
Average Volume (3M)1.95M
Market Cap
$10.38B
Enterprise Value$8.27K
Total Cash (Recent Filing)$530.16M
Total Debt (Recent Filing)$45.89M
Price to Earnings (P/E)―
Beta2.70
Next Earnings
Sep 21, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding87,253,800
10 Day Avg. Volume1,011,403
30 Day Avg. Volume1,951,759
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)17.54
Price to Sales (P/S)0.00
P/FCF Ratio-51.21
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$161.58Price Target Upside28.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.82
Revenue Forecast (FY)$4.35M
Bulls Say, Bears Say
Bulls Say
Phase 3 Maintenance EfficacyRobust Phase 3 maintenance results in a refractory ulcerative colitis cohort materially strengthen the registrational profile for obefazimod. Durable efficacy in difficult-to-treat patients improves the likelihood of label breadth, supports long-term disease control positioning, and reduces regulatory and commercial execution risk versus earlier-stage data.
Long-term Remission & SafetySeven-year remission and an expanded safety database demonstrate sustained clinical benefit and a stable long-term tolerability profile. For a chronic indication, durable remission and reassuring exposure-adjusted safety data support payer acceptance, adherence, and competitive differentiation, enhancing lifetime patient value and commercial durability.
Substantial Capital RaiseA near-$760M equity raise meaningfully strengthens funding capacity for late-stage development, regulatory filings, and U.S. commercialization preparation. This sizable, immediate liquidity buffer materially reduces short-to-medium-term financing risk and provides strategic optionality for launch investment or additional indication trials.
Bears Say
High Cash BurnSustained annual cash outflows of roughly $150M+ reflect heavy R&D and trial costs and create persistent funding needs. Even with recent financings, prolonged development timelines or launch delays would pressure liquidity and force further financing, potentially diluting shareholders or constraining commercialization investment.
Widening Losses And No RevenueZero reported revenue and rapidly expanding losses indicate the company remains pre-commercial and highly dependent on trial outcomes. Persistent negative profitability undermines internal cash generation, increases reliance on external capital, and lengthens the timeline to self-sustaining operations absent regulatory approval and product sales.
Single-asset ConcentrationConcentration on one lead candidate creates binary outcome risk: regulatory setbacks, unexpected safety findings, or competitor displacement would disproportionately damage revenue prospects and valuation. Limited commercial-stage diversification reduces resilience and increases the importance of flawless late-stage execution and successful approval.
Abivax SA Sponsored ADR News
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $67.15 and its highest was $148.83 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $10.38B.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Sep 21, 2026 which is in 34 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on May 22, 2026. The company reported -$0.703 earnings per share for the quarter, beating the consensus estimate of -$0.936 by $0.233.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -0.96.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 87,253,800 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$0.703 in its last earnings report, beating expectations of -$0.936. Following the earnings report the stock price went up 3.623%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abivax SA Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$161.58 (28.55% Upside)
$161.58 (28.55% Upside)
Blogger Sentiment
Bullish
ABVX Sentiment 89%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 487.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
249.60%
Trailing 12-Months
Company Description
Abivax SA Sponsored ADR
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
ABVX Stock 12 Month Forecast
Average Price Target
$161.58
▲(28.55% Upside)
Technical Analysis
Ownership Overview
―
Insiders
5.47% Mutual Funds
45.30% Other Institutional Investors
48.23% Public Companies and
Individual Investors